Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
Por:
Berenguer J, Díez C, Martín-Vicente M, Micán R, Pérez-Elías MJ, García-Fraile LJ, Vidal F, Suárez-García I, Podzamczer D, Del Romero J, Pulido F, Iribarren JA, Gutiérrez F, Poveda E, Galera C, Izquierdo R, Asensi V, Portilla J, López JC, Arribas JR, Moreno S, González-García J, Resino S and Jarrín I
Publicada:
1 nov 2021
Ahead of Print:
1 nov 2021
Resumen:
Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH).
Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection.
Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm(3), 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9-10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41-3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26-0.94, p 0.031).
Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
Filiaciones:
Berenguer J:
Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain. Electronic address:
Díez C:
Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain
Martín-Vicente M:
Centro Nacional de Microbiología (ISCIII), Majadahonda, Spain
Micán R:
Hospital Universitario La Paz, IdiPaz, Madrid, Spain
Pérez-Elías MJ:
Hospital Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, Spain
García-Fraile LJ:
Hospital Universitario de La Princesa, Madrid, Spain
Vidal F:
Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
Suárez-García I:
Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, San Sebastián de los Reyes, Universidad Europea de Madrid, Spain
Podzamczer D:
Hospital Universitari de Bellvitge, Barcelona, Spain
Del Romero J:
Centro Sandoval, Madrid, Spain
Pulido F:
Hospital Universitario 12 Octubre, imas12, Universidad Complutense de Madrid, Madrid, Spain
Iribarren JA:
Hospital Universitario Donostia, II BioDonostia, San Sebastián, Spain
:
Hospital Universitario de Elche, Universidad Miguel Hernández, Elche, Spain
Poveda E:
Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Spain
Galera C:
Hospital Universitario Virgen de La Arrixaca, Murcia, Spain
Izquierdo R:
Centro Nacional de Epidemiología (ISCIII), Madrid, Spain
Asensi V:
Hospital Universitario Central de Asturias, Oviedo, Spain
Portilla J:
Hospital General Universitario de Alicante, Alicante, Spain
López JC:
Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain
Arribas JR:
Hospital Universitario La Paz, IdiPaz, Madrid, Spain
Moreno S:
Hospital Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, Spain
González-García J:
Hospital Universitario La Paz, IdiPaz, Madrid, Spain
Resino S:
Centro Nacional de Microbiología (ISCIII), Majadahonda, Spain
Jarrín I:
Centro Nacional de Epidemiología (ISCIII), Madrid, Spain
Green Published, hybrid
|